Sukran Senyurek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sukran Senyurek has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Ugur Selek
Koc University, School of Medicine
15 shared publications - Erkan Topkan
Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkiye
13 shared publications - Efsun Somay
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Başkent University, Ankara, Türkiye
9 shared publications - Nulifer Kilic Durankus
Department of Radiation Oncology, School of Medicine, Koç University, Istanbul, Turkey
8 shared publications - Duriye Ozturk
Department of Radiation Oncology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey
7 shared publications - Sibel Bascil
Department of Periodontology, Faculty of Dentistry Baskent University Ankara Turkey
5 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- Vol. 63 (5) , 1199-1208
Predicting osteoradionecrosis in nasopharyngeal carcinoma: The role of the GLUCAR index
- 30 October 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- Vol. 63 (5) , 1199-1208
Open AccessPredicting osteoradionecrosis in nasopharyngeal carcinoma: The role of the GLUCAR index
- Open Access
Induction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Outcomes Analysis
Purpose/Objective: To evaluate the safety and failure patterns of consolidative hypofractionated thoracic radiotherapy (RT) following induction chemoimmunotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Materials/Methods: This retrospective study included 34 patients treated between 2019 and 2025. All patients received induction chemoimmunotherapy followed by consolidative hypofractionated RT based on multidisciplinary tumor board recommendations. The primary endpoint was local recurrence (LR); secondary endpoints were regional recurrence (RR), distant metastasis (DM), overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Results: Median age was 64 years, and median PD-L1 expression was 20%. Most patients had stage III disease; squamous cell carcinoma (56%) and adenocarcinoma (38%) were the predominant histologies. The most common systemic regimen was carboplatin/paclitaxel plus nivolumab, with a median of four induction cycles. Post-induction response was complete in 21%, partial in 62%, stable in 12%, and progressive in 6%. Median RT dose was 52.5 Gy in 15 fractions, and maintenance immunotherapy was administered in 79%. At a median follow-up of 16.7 months, using cumulative incidence functions with death treated as a competing event, the 1- and 2-year cumulative incidences of local failure were 6.9% and 14.7%, respectively. The corresponding cumulative incidences of regional failure were 10.2% and 18.8%, while distant metastasis incidences were 15.9% and 39.2%. No isolated local or regional recurrences occurred. One- and two-year OS rates were 86% and 81%, and corresponding PFS rates were 76% and 54%. No grade 4–5 RT-related toxicity occurred; one grade 5 immune-related pneumonitis was observed. Conclusions: Consolidative hypofractionated RT following chemoimmunotherapy appears feasible and associated with favorable outcomes, supporting further prospective investigation.
Open AccessInduction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Outcomes Analysis
Purpose/Objective: To evaluate the safety and failure patterns of consolidative hypofractionated thoracic radiotherapy (RT) following induction chemoimmunotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Materials/Methods: This retrospective study included 34 patients treated between 2019 and 2025. All patients received induction chemoimmunotherapy followed by consolidative hypofractionated RT based on multidisciplinary tumor board recommendations. The primary endpoint was local recurrence (LR); secondary endpoints were regional recurrence (RR), distant metastasis (DM), overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Results: Median age was 64 years, and median PD-L1 expression was 20%. Most patients had stage III disease; squamous cell carcinoma (56%) and adenocarcinoma (38%) were the predominant histologies. The most common systemic regimen was carboplatin/paclitaxel plus nivolumab, with a median of four induction cycles. Post-induction response was complete in 21%, partial in 62%, stable in 12%, and progressive in 6%. Median RT dose was 52.5 Gy in 15 fractions, and maintenance immunotherapy was administered in 79%. At a median follow-up of 16.7 months, using cumulative incidence functions with death treated as a competing event, the 1- and 2-year cumulative incidences of local failure were 6.9% and 14.7%, respectively. The corresponding cumulative incidences of regional failure were 10.2% and 18.8%, while distant metastasis incidences were 15.9% and 39.2%. No isolated local or regional recurrences occurred. One- and two-year OS rates were 86% and 81%, and corresponding PFS rates were 76% and 54%. No grade 4–5 RT-related toxicity occurred; one grade 5 immune-related pneumonitis was observed. Conclusions: Consolidative hypofractionated RT following chemoimmunotherapy appears feasible and associated with favorable outcomes, supporting further prospective investigation.
- 12 May 2026
- Published by Wiley in Special Care in Dentistry
- Vol. 46 (3) , e70183
Comment on: “Surgical Extraction‐Related Dental Clearance Delays Before Radiotherapy in Head and Neck Cancer: A Descriptive Study From a Canadian Tertiary Center”
- 12 May 2026
- Published by Wiley in Special Care in Dentistry
- Vol. 46 (3) , e70183
Comment on: “Surgical Extraction‐Related Dental Clearance Delays Before Radiotherapy in Head and Neck Cancer: A Descriptive Study From a Canadian Tertiary Center”
- Open Access
- 12 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1091
Heat Shock Protein 27 in Radiation-Induced Trismus: Mechanistic Insights and a Hypothesis-Generating Framework
Radiation-induced trismus (RIT) is a common and function-limiting late complication of radiotherapy for head and neck cancers, particularly when the masticatory muscles and temporomandibular joint receive high doses. Despite advances in intensity-modulated radiotherapy, RIT remains a significant survivorship problem, and robust biological biomarkers capable of predicting individual susceptibility are lacking. Heat shock protein 27 (HSP27; HSPB1) is a small heat shock protein that regulates multiple cellular stress responses, including proteostasis, cytoskeletal dynamics, redox homeostasis, apoptosis, and inflammatory signaling. In head and neck malignancies, HSP27 overexpression has been associated with treatment resistance and fibrosis-prone tissue remodeling. Experimental studies further demonstrate that HSP27 promotes transforming growth factor-β-mediated myofibroblast differentiation and extracellular matrix deposition, whereas pharmacologic or genetic inhibition attenuates radiation- or bleomycin-induced pulmonary fibrosis in vivo. Evidence from skeletal muscle biology also indicates that HSP27 modulates muscle integrity, denervation-associated atrophy, inflammatory signaling, and cytoskeletal stability. Although HSP27 has been widely investigated in radiation responses, fibrosis, and skeletal muscle stress adaptation, its potential involvement in the pathogenesis of RIT has not been systematically examined. This review proposes a conceptual framework in which HSP27 functions as an integrative molecular mediator linking radiation-induced oxidative stress, endothelial injury, and fibro-atrophic remodeling within the masticatory apparatus. By integrating current evidence on the epidemiology, dosimetric determinants, imaging correlates, and pathophysiology of RIT with the structural and functional biology of HSP27, this review provides the first tissue-specific synthesis of molecular stress signaling and clinical mechanisms relevant to RIT susceptibility. We further suggest that HSP27 signaling may influence susceptibility to fibro-neuromuscular injury in irradiated masticatory tissues. Given the absence of direct experimental or clinical evidence in this setting, these considerations are derived from mechanistic convergence across related biological systems and should be interpreted as biologically plausible but unproven, with potential implications for future biomarker development and biologically informed prevention strategies.
- 12 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1091
Open AccessHeat Shock Protein 27 in Radiation-Induced Trismus: Mechanistic Insights and a Hypothesis-Generating Framework
Radiation-induced trismus (RIT) is a common and function-limiting late complication of radiotherapy for head and neck cancers, particularly when the masticatory muscles and temporomandibular joint receive high doses. Despite advances in intensity-modulated radiotherapy, RIT remains a significant survivorship problem, and robust biological biomarkers capable of predicting individual susceptibility are lacking. Heat shock protein 27 (HSP27; HSPB1) is a small heat shock protein that regulates multiple cellular stress responses, including proteostasis, cytoskeletal dynamics, redox homeostasis, apoptosis, and inflammatory signaling. In head and neck malignancies, HSP27 overexpression has been associated with treatment resistance and fibrosis-prone tissue remodeling. Experimental studies further demonstrate that HSP27 promotes transforming growth factor-β-mediated myofibroblast differentiation and extracellular matrix deposition, whereas pharmacologic or genetic inhibition attenuates radiation- or bleomycin-induced pulmonary fibrosis in vivo. Evidence from skeletal muscle biology also indicates that HSP27 modulates muscle integrity, denervation-associated atrophy, inflammatory signaling, and cytoskeletal stability. Although HSP27 has been widely investigated in radiation responses, fibrosis, and skeletal muscle stress adaptation, its potential involvement in the pathogenesis of RIT has not been systematically examined. This review proposes a conceptual framework in which HSP27 functions as an integrative molecular mediator linking radiation-induced oxidative stress, endothelial injury, and fibro-atrophic remodeling within the masticatory apparatus. By integrating current evidence on the epidemiology, dosimetric determinants, imaging correlates, and pathophysiology of RIT with the structural and functional biology of HSP27, this review provides the first tissue-specific synthesis of molecular stress signaling and clinical mechanisms relevant to RIT susceptibility. We further suggest that HSP27 signaling may influence susceptibility to fibro-neuromuscular injury in irradiated masticatory tissues. Given the absence of direct experimental or clinical evidence in this setting, these considerations are derived from mechanistic convergence across related biological systems and should be interpreted as biologically plausible but unproven, with potential implications for future biomarker development and biologically informed prevention strategies.
- Open Access
- 9 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (5) , 278
Significant Correlation of Dynamic Pan-Immune Inflammation Value and Magnetic Resonance Imaging Response in Patients with Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy
Background: Accurate identification of complete or near-complete responders after total neoadjuvant therapy (TNT) is critical for selecting candidates for non-operative management in locally advanced rectal cancer (LARC). While static inflammatory biomarkers have been widely investigated, the predictive value of dynamic changes in systemic inflammation during TNT remains unclear. This study evaluated whether changes in the Pan-Immune Inflammation Value (PIV) correlate with magnetic resonance imaging tumor regression grade (mrTRG) and regrowth risk. Methods: Seventy-three patients with LARC treated with TNT between 2018 and 2024 were retrospectively analyzed. Patients were classified as complete/near-complete responders (C-NCRG; mrTRG1–2) or residual disease group (RDG; mrTRG3–5). The PIV was calculated as (platelet × monocyte × neutrophil)/lymphocyte at treatment initiation (first-PIV), three weeks after completion of chemotherapy (last-PIV), and at regrowth (Rg-PIV). Dynamic changes were defined as Δ-PIV (last-PIV minus first-PIV) and ΔRg-PIV (Rg-PIV minus first-PIV). Receiver operating characteristic analysis identified optimal cutoffs, and logistic regression assessed independent associations. Results: The baseline PIV did not differ between groups. Last-PIV and Δ-PIV were significantly lower in the C-NCRG compared with RDG (p = 0.006). A Δ-PIV cutoff of −36.9 discriminated responders (AUC = 0.705; sensitivity 53.7%; specificity 84.4%) and remained independently associated with MRI response in multivariate analysis. In the non-operative management cohort, ΔRg-PIV was significantly lower in patients without regrowth (p = 0.001), with a cutoff of −77.72 (AUC = 0.794; sensitivity 88.9%; specificity 66.7%). Overall survival was superior in the C-NCRG (p = 0.01). Conclusions: A dynamic reduction in the PIV during TNT is significantly associated with favorable MRI response and lower regrowth risk in LARC. PIV dynamics may serve as a noninvasive complementary biomarker to support response assessment and stratification in organ-preservation strategies.
- 9 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (5) , 278
Open AccessSignificant Correlation of Dynamic Pan-Immune Inflammation Value and Magnetic Resonance Imaging Response in Patients with Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy
Background: Accurate identification of complete or near-complete responders after total neoadjuvant therapy (TNT) is critical for selecting candidates for non-operative management in locally advanced rectal cancer (LARC). While static inflammatory biomarkers have been widely investigated, the predictive value of dynamic changes in systemic inflammation during TNT remains unclear. This study evaluated whether changes in the Pan-Immune Inflammation Value (PIV) correlate with magnetic resonance imaging tumor regression grade (mrTRG) and regrowth risk. Methods: Seventy-three patients with LARC treated with TNT between 2018 and 2024 were retrospectively analyzed. Patients were classified as complete/near-complete responders (C-NCRG; mrTRG1–2) or residual disease group (RDG; mrTRG3–5). The PIV was calculated as (platelet × monocyte × neutrophil)/lymphocyte at treatment initiation (first-PIV), three weeks after completion of chemotherapy (last-PIV), and at regrowth (Rg-PIV). Dynamic changes were defined as Δ-PIV (last-PIV minus first-PIV) and ΔRg-PIV (Rg-PIV minus first-PIV). Receiver operating characteristic analysis identified optimal cutoffs, and logistic regression assessed independent associations. Results: The baseline PIV did not differ between groups. Last-PIV and Δ-PIV were significantly lower in the C-NCRG compared with RDG (p = 0.006). A Δ-PIV cutoff of −36.9 discriminated responders (AUC = 0.705; sensitivity 53.7%; specificity 84.4%) and remained independently associated with MRI response in multivariate analysis. In the non-operative management cohort, ΔRg-PIV was significantly lower in patients without regrowth (p = 0.001), with a cutoff of −77.72 (AUC = 0.794; sensitivity 88.9%; specificity 66.7%). Overall survival was superior in the C-NCRG (p = 0.01). Conclusions: A dynamic reduction in the PIV during TNT is significantly associated with favorable MRI response and lower regrowth risk in LARC. PIV dynamics may serve as a noninvasive complementary biomarker to support response assessment and stratification in organ-preservation strategies.
- Open Access
- 21 March 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 296
Stereotactic radiosurgery for pilocytic astrocytoma: A single center retrospective study
Introduction: Pilocytic astrocytoma (PA) is a WHO grade I glioma with generally favorable outcomes; however, deep or eloquent tumor locations often limit safe gross total resection. Gamma Knife radiosurgery (GKRS) has emerged as a minimally invasive alternative for residual or recurrent disease. Materials and methods: A retrospective review of 88 patients (60 diagnosed in childhood and 28 in adulthood) treated with GKRS between 2008 and 2024 was conducted. Clinical, radiological, and treatment parameters were analyzed. PFS was assessed with Kaplan–Meier analysis, and predictive factors were identified using univariate and multivariate Cox regression models. Results: Median follow-up was 36 months. Pediatric patients showed 5- and 10-year PFS rates of 84.7% and 66.7%, while adults demonstrated 81.7% at both time points. Multivariate analysis identified prior radiotherapy as the only independent predictor of recurrence in the entire cohort, with significant impact also observed in the pediatric subgroup. Cystic/mixed morphology increased recurrence risk in pediatric patients, while no independent predictors were identified in adults. Discussion and conclusion: GKRS provides durable long-term tumor control in both pediatric and adult PA patients. Prior radiotherapy consistently predicts poorer PFS, underscoring its importance in treatment planning. In pediatric patients, tumor morphology also influences outcomes. Despite the retrospective design and cohort heterogeneity, this represents one of the largest single-center GKRS series and supports GKRS as a safe and effective modality for PA management. Prospective studies are needed to refine patient selection and optimize therapeutic strategies.
- 21 March 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 296
Open AccessStereotactic radiosurgery for pilocytic astrocytoma: A single center retrospective study
Introduction: Pilocytic astrocytoma (PA) is a WHO grade I glioma with generally favorable outcomes; however, deep or eloquent tumor locations often limit safe gross total resection. Gamma Knife radiosurgery (GKRS) has emerged as a minimally invasive alternative for residual or recurrent disease. Materials and methods: A retrospective review of 88 patients (60 diagnosed in childhood and 28 in adulthood) treated with GKRS between 2008 and 2024 was conducted. Clinical, radiological, and treatment parameters were analyzed. PFS was assessed with Kaplan–Meier analysis, and predictive factors were identified using univariate and multivariate Cox regression models. Results: Median follow-up was 36 months. Pediatric patients showed 5- and 10-year PFS rates of 84.7% and 66.7%, while adults demonstrated 81.7% at both time points. Multivariate analysis identified prior radiotherapy as the only independent predictor of recurrence in the entire cohort, with significant impact also observed in the pediatric subgroup. Cystic/mixed morphology increased recurrence risk in pediatric patients, while no independent predictors were identified in adults. Discussion and conclusion: GKRS provides durable long-term tumor control in both pediatric and adult PA patients. Prior radiotherapy consistently predicts poorer PFS, underscoring its importance in treatment planning. In pediatric patients, tumor morphology also influences outcomes. Despite the retrospective design and cohort heterogeneity, this represents one of the largest single-center GKRS series and supports GKRS as a safe and effective modality for PA management. Prospective studies are needed to refine patient selection and optimize therapeutic strategies.
- Open Access
- 20 November 2025
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (6) , 959-972
CARWL score as a predictor of radiation-induced periodontitis in locally advanced head and neck cancer undergoing concurrent chemoradiotherapy
Although concurrent chemoradiotherapy (CCRT) has improved outcomes in locally advanced head and neck cancer (LA-HNC), radiation-induced periodontitis (RIP) remains an under-recognized oral toxicity with significant consequences, including tooth loss and osteoradionecrosis. This study evaluates the utility of the novel CARWL score—a combined index of the C-reactive protein-to-albumin ratio (CAR) and significant weight loss (SWL)—for stratifying the risk of RIP in LA-HNC patients without baseline periodontitis undergoing CCRT. We conducted a retrospective analysis of 67 LA-HNC patients who underwent CCRT and received detailed oral examinations before and after treatment; none had periodontitis at the initiation of CCRT. Receiver operating characteristic (ROC) curve analysis identified an optimal pretreatment CAR cutoff of 3.07, with SWL defined as greater than 5% body weight loss in the preceding six months. Based on CAR (≥3.07 vs. <3.07) and SWL (present vs. absent), patients were categorized into three CARWL groups. The primary endpoint was the association between the baseline CARWL group and the rates of RIP following CCRT. RIP was diagnosed in 17 patients (25.4%) during follow-up, with incidences increasing progressively across CARWL-0, CARWL-1, and CARWL-2 groups (11.8% vs. 20.8% vs. 38.5%; p = 0.007). In multivariable Cox proportional-hazards analysis, a higher CARWL score emerged as an independent predictor of increased RIP risk (adjusted HR = 3.64; 95% CI 1.41–9.37; p = 0.007), and supplementary logistic regression sensitivity analysis corroborated these findings (adjusted OR = 3.58; 95% CI 1.35–9.45). These findings demonstrate that the pretreatment CARWL score serves as a straightforward and readily available biomarker that effectively stratifies the risk of radiation-induced periodontitis in LA-HNC patients treated with CCRT.
- 20 November 2025
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (6) , 959-972
Open AccessCARWL score as a predictor of radiation-induced periodontitis in locally advanced head and neck cancer undergoing concurrent chemoradiotherapy
Although concurrent chemoradiotherapy (CCRT) has improved outcomes in locally advanced head and neck cancer (LA-HNC), radiation-induced periodontitis (RIP) remains an under-recognized oral toxicity with significant consequences, including tooth loss and osteoradionecrosis. This study evaluates the utility of the novel CARWL score—a combined index of the C-reactive protein-to-albumin ratio (CAR) and significant weight loss (SWL)—for stratifying the risk of RIP in LA-HNC patients without baseline periodontitis undergoing CCRT. We conducted a retrospective analysis of 67 LA-HNC patients who underwent CCRT and received detailed oral examinations before and after treatment; none had periodontitis at the initiation of CCRT. Receiver operating characteristic (ROC) curve analysis identified an optimal pretreatment CAR cutoff of 3.07, with SWL defined as greater than 5% body weight loss in the preceding six months. Based on CAR (≥3.07 vs. <3.07) and SWL (present vs. absent), patients were categorized into three CARWL groups. The primary endpoint was the association between the baseline CARWL group and the rates of RIP following CCRT. RIP was diagnosed in 17 patients (25.4%) during follow-up, with incidences increasing progressively across CARWL-0, CARWL-1, and CARWL-2 groups (11.8% vs. 20.8% vs. 38.5%; p = 0.007). In multivariable Cox proportional-hazards analysis, a higher CARWL score emerged as an independent predictor of increased RIP risk (adjusted HR = 3.64; 95% CI 1.41–9.37; p = 0.007), and supplementary logistic regression sensitivity analysis corroborated these findings (adjusted OR = 3.58; 95% CI 1.35–9.45). These findings demonstrate that the pretreatment CARWL score serves as a straightforward and readily available biomarker that effectively stratifies the risk of radiation-induced periodontitis in LA-HNC patients treated with CCRT.
- Open Access
- 4 August 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 301-306
Lymphedema and Axillary-Lateral Thoracic Vessel Juncture Irradiation: A Clinical Dilemma
Regional nodal irradiation (RNI) is one of the main causes of breast cancer-related lymphedema (BCRL). However, studies on the relationship between the radiation dose to the axillary-lateral thoracic vessel juncture (ALTJ) region and BCRL have reported conflicting results. Based on these findings, we aimed to evaluate the clinical relevance of the dose to the ALTJ region in our patient cohort. Patients diagnosed with breast cancer and who were treated at Koç University Hospital between 2016 and 2022 and received RNI were included. BCRL was defined as a difference in arm circumference between the ipsilateral and contralateral limb >2.5 cm at any single encounter or ≥2 cm on ≥2 visits. ALTJ was retrospectively contoured, and doses were recorded as equivalent dose (α/β = 3). Of the 129 patients (median age 49 years) who met the inclusion criteria, 12 (9.3%) had lymphedema. Two-thirds of the patients (66.7%) were stage II, and one-third (33.3%) were stage III. The median follow-up was 22 months. The median (range) ALTJ Dmean dose was 18.11 (1.87-50) Gy, the median ALTJ Dmax was 44.53 (12.8-71.1) Gy, and the median ALTJ V35 was 38% (1-100%). No significant association was determined between ALTJ parameters and BCRL. There is insufficient data to define ALTJ as an OAR for decreasing BCRL risk. It is not appropriate to define dose and target based on ALTJ. Prospective studies with larger patient populations are needed to clarify the relationship between ALTJ and lymphedema.
- 4 August 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 301-306
Open AccessLymphedema and Axillary-Lateral Thoracic Vessel Juncture Irradiation: A Clinical Dilemma
Regional nodal irradiation (RNI) is one of the main causes of breast cancer-related lymphedema (BCRL). However, studies on the relationship between the radiation dose to the axillary-lateral thoracic vessel juncture (ALTJ) region and BCRL have reported conflicting results. Based on these findings, we aimed to evaluate the clinical relevance of the dose to the ALTJ region in our patient cohort. Patients diagnosed with breast cancer and who were treated at Koç University Hospital between 2016 and 2022 and received RNI were included. BCRL was defined as a difference in arm circumference between the ipsilateral and contralateral limb >2.5 cm at any single encounter or ≥2 cm on ≥2 visits. ALTJ was retrospectively contoured, and doses were recorded as equivalent dose (α/β = 3). Of the 129 patients (median age 49 years) who met the inclusion criteria, 12 (9.3%) had lymphedema. Two-thirds of the patients (66.7%) were stage II, and one-third (33.3%) were stage III. The median follow-up was 22 months. The median (range) ALTJ Dmean dose was 18.11 (1.87-50) Gy, the median ALTJ Dmax was 44.53 (12.8-71.1) Gy, and the median ALTJ V35 was 38% (1-100%). No significant association was determined between ALTJ parameters and BCRL. There is insufficient data to define ALTJ as an OAR for decreasing BCRL risk. It is not appropriate to define dose and target based on ALTJ. Prospective studies with larger patient populations are needed to clarify the relationship between ALTJ and lymphedema.
- 8 April 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (5) , 1-3
Letter to the editor: Evaluation of sarcopenia’s relationship with overall survival and treatment toxicity in soft tissue sarcomas
- 8 April 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (5) , 1-3
Letter to the editor: Evaluation of sarcopenia’s relationship with overall survival and treatment toxicity in soft tissue sarcomas